JP2010540654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540654A5 JP2010540654A5 JP2010528129A JP2010528129A JP2010540654A5 JP 2010540654 A5 JP2010540654 A5 JP 2010540654A5 JP 2010528129 A JP2010528129 A JP 2010528129A JP 2010528129 A JP2010528129 A JP 2010528129A JP 2010540654 A5 JP2010540654 A5 JP 2010540654A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid composition
- compstatin analog
- composition
- seq
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 216
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical class C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims description 169
- 239000007788 liquid Substances 0.000 claims description 156
- 238000000034 method Methods 0.000 claims description 47
- 230000007423 decrease Effects 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 229940124073 Complement inhibitor Drugs 0.000 claims description 7
- 239000004074 complement inhibitor Substances 0.000 claims description 7
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 6
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 150000005846 sugar alcohols Chemical class 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 229960005475 antiinfective agent Drugs 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 239000000730 antalgic agent Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 8
- 108010027437 compstatin Proteins 0.000 description 7
- 108010069514 Cyclic Peptides Proteins 0.000 description 4
- 102000001189 Cyclic Peptides Human genes 0.000 description 4
- -1 antibody Chemical class 0.000 description 4
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 3
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97691907P | 2007-10-02 | 2007-10-02 | |
| US2646008P | 2008-02-05 | 2008-02-05 | |
| PCT/US2008/078593 WO2009046198A2 (en) | 2007-10-02 | 2008-10-02 | Sustained delivery of compstatin analogs from gels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010540654A JP2010540654A (ja) | 2010-12-24 |
| JP2010540654A5 true JP2010540654A5 (enExample) | 2011-10-27 |
Family
ID=40526950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528129A Pending JP2010540654A (ja) | 2007-10-02 | 2008-10-02 | ゲルからのコンプスタチンアナログの持続的送達 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110182877A1 (enExample) |
| EP (1) | EP2207530A4 (enExample) |
| JP (1) | JP2010540654A (enExample) |
| KR (2) | KR20150080007A (enExample) |
| CN (1) | CN101854916A (enExample) |
| AU (1) | AU2008308657A1 (enExample) |
| BR (1) | BRPI0817524A2 (enExample) |
| CA (1) | CA2701470A1 (enExample) |
| MX (1) | MX2010003630A (enExample) |
| RU (1) | RU2505311C2 (enExample) |
| WO (1) | WO2009046198A2 (enExample) |
| ZA (1) | ZA201002365B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US20110092446A1 (en) * | 2007-07-20 | 2011-04-21 | Cedric Francois | Compositions and methods for treatment of trauma |
| WO2009121065A2 (en) * | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| TWI492769B (zh) * | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| DK2425814T3 (da) | 2010-09-03 | 2013-09-08 | Novagali Pharma Sa | Vand-i-olieemulsion til behandling af en øjensygdom |
| US9107822B2 (en) | 2010-09-03 | 2015-08-18 | Santen Sas | Water-in oil type emulsion for treating a disease of the eye |
| EA028375B1 (ru) | 2010-09-03 | 2017-11-30 | Сантен Сас | Композиция в виде эмульсии типа "вода-в-масле" для интраокулярного введения |
| CA2835627C (en) | 2011-05-11 | 2023-01-10 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
| EP2723361B1 (en) * | 2011-06-22 | 2019-10-30 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| WO2014028861A1 (en) | 2012-08-17 | 2014-02-20 | Apellis Pharmaceuticals, Inc. | Detection of high risk drusen |
| EP3929206A1 (en) | 2012-11-15 | 2021-12-29 | Apellis Pharmaceuticals, Inc. | Long-acting compstatin analogs and related compositions and methods |
| US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| US9940683B2 (en) | 2013-07-31 | 2018-04-10 | Elwha Llc | Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period |
| US20150039337A1 (en) * | 2013-07-31 | 2015-02-05 | Elwha Llc | Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period |
| EP2918262B1 (en) | 2014-03-10 | 2023-08-09 | PLS-Design GmbH | Induction of antigen-specific tolerance by peripheral phagocytosis |
| HUE045646T2 (hu) | 2014-06-12 | 2020-01-28 | Ra Pharmaceuticals Inc | Komplement aktivitás modulálása |
| CA2970502A1 (en) * | 2014-12-12 | 2016-06-16 | The Schepens Eye Research Institute, Inc. | Gdnf induction for the treatment of retinal disorders |
| WO2016123371A1 (en) | 2015-01-28 | 2016-08-04 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| EP3095440B1 (en) | 2015-05-19 | 2020-01-15 | PLS-Design GmbH | Antigen-specific immunotherapy using tolerizing liposomes |
| CA3287719A1 (en) * | 2015-10-07 | 2026-03-02 | Apellis Pharmaceuticals, Inc. | Use of long-acting compstatin analog for treating a complement-mediated disorder |
| EP4218790B1 (en) * | 2015-12-16 | 2026-02-18 | UCB Holdings, Inc. | Modulators of complement activity |
| CA3045114A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| RU2661621C2 (ru) * | 2016-12-19 | 2018-07-17 | Александр Николаевич Епихин | Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций |
| CN116059313A (zh) | 2017-04-07 | 2023-05-05 | 阿佩利斯制药有限公司 | 给药方案以及相关组合物和方法 |
| KR20240167712A (ko) | 2017-12-15 | 2024-11-27 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
| US12558398B2 (en) | 2019-06-04 | 2026-02-24 | Ucb Holdings, Inc. | Inflammatory disease treatment with complement inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7488590B2 (en) * | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| DK1549333T3 (da) * | 2002-09-20 | 2012-01-16 | Univ Pennsylvania | Compstatinanaloge med forbedret aktivitet |
| CA2625206C (en) * | 2005-10-08 | 2021-12-07 | Potentia Pharmaceuticals, Inc. | Compstatin and analogs thereof for eye disorders |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| CN106188239B (zh) * | 2005-11-28 | 2020-01-07 | 宾夕法尼亚州大学理事会 | 有效的坎普他汀类似物 |
| KR20080087814A (ko) * | 2005-12-22 | 2008-10-01 | 알콘 리서치, 리미티드 | 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제 |
| US20070196367A1 (en) * | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| AU2008214359B2 (en) * | 2007-02-05 | 2014-01-16 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
-
2008
- 2008-10-02 WO PCT/US2008/078593 patent/WO2009046198A2/en not_active Ceased
- 2008-10-02 KR KR1020157016589A patent/KR20150080007A/ko not_active Ceased
- 2008-10-02 AU AU2008308657A patent/AU2008308657A1/en not_active Abandoned
- 2008-10-02 JP JP2010528129A patent/JP2010540654A/ja active Pending
- 2008-10-02 MX MX2010003630A patent/MX2010003630A/es unknown
- 2008-10-02 US US12/681,392 patent/US20110182877A1/en not_active Abandoned
- 2008-10-02 RU RU2010113513/15A patent/RU2505311C2/ru not_active IP Right Cessation
- 2008-10-02 CA CA2701470A patent/CA2701470A1/en not_active Abandoned
- 2008-10-02 EP EP08836209.0A patent/EP2207530A4/en not_active Withdrawn
- 2008-10-02 BR BRPI0817524A patent/BRPI0817524A2/pt not_active IP Right Cessation
- 2008-10-02 CN CN200880115155A patent/CN101854916A/zh active Pending
- 2008-10-02 KR KR1020107008703A patent/KR20100094453A/ko not_active Ceased
-
2010
- 2010-04-01 ZA ZA2010/02365A patent/ZA201002365B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220025028A1 (en) | Methods of Treating or Preventing Periodontitis and Diseases Associated with Periodontitis | |
| US10945962B2 (en) | Controlled-release peptide compositions and uses thereof | |
| CN101296704B (zh) | 用于减少cd36表达的方法 | |
| US11241487B2 (en) | Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders | |
| US10363282B2 (en) | Analogs of C5a and methods of using same | |
| RU2010113513A (ru) | Пролонгированная доставка аналогов компстатина из гелей | |
| US10800812B2 (en) | Compstatin analogs with increased solubility and improved pharmacokinetic properties | |
| US20190117741A1 (en) | Compositions and methods for treating and preventing lung disease | |
| US20200172587A1 (en) | Hydrochloride salts of c5a receptor agonist peptides | |
| CN118076372A (zh) | 治疗和预防肺病的组合物和方法 | |
| WO2025123051A1 (en) | Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain | |
| HK40074502A (en) | Compstatin analogs with increased solubility and improved pharmacokinetic properties | |
| JP2025503607A5 (enExample) | ||
| HK40030234B (en) | Compstatin analogs with increased solubility and improved pharmacokinetic properties | |
| HK1212718B (zh) | 用於减少cd36表达的方法 | |
| NZ621790B2 (en) | Cardiovascular therapeutics |